Search
Research
Paediatrician beliefs and practices around influenza vaccinationWe aimed to determine Australian paediatricians' beliefs and practices around the influenza vaccination of children.
Research
Differences in the population structure of Neisseria meningitidis in two Australian states: Victoria and Western AustraliaIn this study, invasive meningococcal disease isolates from the western seaboard of Australia, WA, were compared to those of VIC from 2008 to 2012.
Research
Epidemiology of invasive meningococcal b disease in Australia, 1999-2015: Priority populations for vaccinationTo describe trends in the age-specific incidence of serogroup B invasive meningococcal disease (IMD) in Australia, 1999-2015
Research
Genetic Variants in the IL-4/IL-13 Pathway Influence Measles Vaccine Responses and Vaccine Failure in Children from MozambiqueWe investigated IL-4, IL-13, and IL-4Rα polymorphisms and their impact on measles IgG responses and measles vaccine failure, in two separate cohort.
Research
Dedicated paediatric Outpatient Parenteral Antimicrobial Therapy medical support: a pre-post observational studyThe introduction of a formal medical team to Hospital in the Home (HiTH) demonstrated a positive clinical impact on Parenteral Antimicrobial Therapy (OPAT) patients' outcomes.
Research
Biofilm forming potential and antimicrobial susceptibility of newly emerged Western Australian Bordetella pertussis clinical isolatesIsobaric tags for relative and absolute quantitation (iTRAQ)-based proteomic analysis revealed significant differences in protein expression in B. pertussis biofilms
Research
A Phase III, randomized, controlled, observer-blind study to demonstrate effectiveness, immunogenicity and safety of GSK's meningococcal Group B and combined ABCWY vaccines when administered to healthy adolescents and young adults (Quintet)Jennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
A randomized, controlled, observer-blind, phase 1/2a study to evaluate the safety, reactogenicity, and immunogenicity of Ad26.RSV.preF in RSV-seronegative toddlers 12 to 24 months of ageJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Pertaprime: An investigator-driven phase II-III randomised, observer-blind, controlled trial to demonstrate non-inferior immunogenicity of Pertagen® in comparison to Boostrix® in healthy young Australian adults aged 18-25 yearsJennifer Peter Kent Richmond RN MBBS MRCP(UK) FRACP Clinical Research Manager Head, Vaccine Trials Group Jennifer.Kent@thekids.org.au Clinical
Research
Are you listening? The inaugural OMOZ Workshop - towards a better understanding of otitis mediaAre you listening? The inaugural OMOZ Workshop - towards a better understanding of otitis media